Type 2 Diabetes Trial, Recruiting NCT07121504 Sponsor: Second Xiangya Hospital of Central South University Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07121504
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been diagnosed with type 2 diabetes and are scheduled for surgery lasting 2 hours or more, where a hospital stay of more than 72 hours is expected, along with short-term nutrition delivered through a drip (intravenous nutrition) around the time of surgery
  • People whose blood sugar is not well controlled, meeting at least one of the following: a long-term blood sugar measure (HbA1c) of 7.5% or higher, or a random blood sugar reading of 13.9 mmol/L or higher; OR type 2 diabetes that remains poorly controlled (HbA1c 7.5% or higher) despite taking two or more diabetes tablets; OR people already on insulin whose blood sugar remains above target (HbA1c 7.0% or higher) even after dose adjustments
  • People who are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • People experiencing a serious sudden diabetes complication, such as diabetic ketoacidosis or a dangerous high blood sugar emergency
  • People with type 1 diabetes or another specific type of diabetes other than type 2
  • People with serious problems affecting the heart (heart failure classified as Class III or above), liver (certain elevated liver enzyme levels), kidneys (kidney filtration rate at or below 30 mL/min/1.73 m²), low red blood cell levels (haemoglobin below 90 g/L), low white blood cell or platelet counts, or unstable blood pressure and circulation
  • People with other hormonal conditions that affect blood sugar levels, such as an overactive or underactive thyroid, or Cushing's syndrome
  • People with a known allergy or sensitivity to any medications or materials used in this trial
  • People for whom standard insulin pump therapy is not medically appropriate
  • People with skin conditions such as rashes or itching disorders, or with blood clotting problems
  • People who have reduced consciousness or a mental health condition that affects their ability to make decisions or communicate
  • People who develop serious complications from surgery
  • People considered unsuitable for the trial by the research team for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xia Li, MD, PhD, Second Xiangya Hospial of Central South University

Phone: +86 13974885753

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
26 June 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

CGM-measured Time in Range (TIR 5.6-10.0 mmol/L)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov